Mexico Viscosupplementation Market Size & Outlook
Mexico viscosupplementation market, 2018-2030 (US$M)
Related Markets
Mexico viscosupplementation market highlights
- The Mexico viscosupplementation market generated a revenue of USD 14.2 million in 2023 and is expected to reach USD 28.7 million by 2030.
- The Mexico market is expected to grow at a CAGR of 10.5% from 2024 to 2030.
- In terms of segment, single injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
Viscosupplementation market data book summary
| Market revenue in 2023 | USD 14.2 million |
| Market revenue in 2030 | USD 28.7 million |
| Growth rate | 10.5% (CAGR from 2023 to 2030) |
| Largest segment | Single injection |
| Fastest growing segment | Single Injection |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.3% of the global viscosupplementation market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil viscosupplementation market is projected to lead the regional market in terms of revenue in 2030.
- Argentina is the fastest growing regional market in Latin America and is projected to reach USD 18.5 million by 2030.
Single injection was the largest segment with a revenue share of 42.96% in 2023. Horizon Databook has segmented the Mexico viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
In 2016, the country has almost 6.7 million patients suffering from osteoarthritis of the knee. Moreover, this growth can be also be attributed to the increasing medical tourism in the country due to low-cost osteoarthritis treatment.
Many medical tourism websites in the country are providing list of orthopedic hospitals and centers for foreigners to visit in Mexico. The manufactures are also capitalizing this opportunity by launching new products in the country.
In November 2016, Bioventus launched its singleinjection product, DUROLANE in Mexico. The company signed a distribution agreement with a Mexican company, Artimedica SA. In addition, many companies are penetrating into the market by distributing these viscosupplements in the country. For instance, Variclinic is responsible for distributing Anika Therapeutics’ viscosupplements in Mexico.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico viscosupplementation market size, by product, 2018-2030 (US$M)
Mexico Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
